Time-dependence of risperidone and asenapine sensitization and associated D2 receptor mechanism

Behavioural Brain Research

Volumn 257, Issue , 2013, Pages 286-294

  Gao, Jun ^a   Li, Ming ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Conditioned avoidance response; Locomotor activity; Quinpirole; Risperidone; Time dependent sensitization (TDS), Asenapine

Indexed keywords

ASENAPINE; DOPAMINE 2 RECEPTOR; QUINPIROLE; RISPERIDONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EXPOSURE; DRUG RECHALLENGE; DRUG SENSITIZATION; ENZYME MECHANISM; HABITUATION; LOCOMOTION; LOW DRUG DOSE; MALE; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION;

CONDITIONED AVOIDANCE RESPONSE; LOCOMOTOR ACTIVITY; QUINPIROLE; RISPERIDONE; TIME-DEPENDENT SENSITIZATION (TDS), ASENAPINE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HYPERKINESIS; MALE; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RISPERIDONE; TIME FACTORS;

EID: 84886802261     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.09.050     Document Type: Article

References (67)

1. Fallon P., Dursun S.M. A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis. J Psychopharmacol 2011, 25:755-762.
2. Agid O., Kapur S., Arenovich T., Zipursky R.B. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003, 60:1228-1235.
3. Kapur S., Agid O., Mizrahi R., Li M. How antipsychotics work - from receptors to reality. NeuroRx 2006, 3:10-21.
4. Lanis A., Schmidt W.J. NMDA receptor antagonists do not block the development of sensitization of catalepsy, but make its expression state-dependent. Behav Pharmacol 2001, 12:143-149.
5. Amtage J., Schmidt W.J. Context-dependent catalepsy intensification is due to classical conditioning and sensitization. Behav Pharmacol 2003, 14:563-567.
6. Antelman S.M., Kocan D., Edwards D.J., Knopf S., Perel J.M., Stiller R. Behavioral effects of a single neuroleptic treatment grow with the passage of time. Brain Res 1986, 385:58-67.
7. Wolgin D.L., Moore J. Sensitization to haloperidol-induced suppression of milk intake: effect of interdose interval. Psychopharmacology (Berl) 1992, 107:290-296.
8. Swalve N., Li M. Parametric studies of antipsychotic-induced sensitization in the conditioned avoidance response model: roles of number of drug exposure, drug dose, and test-retest interval. Behav Pharmacol 2012, 23:380-391.
9. Browman K.E., Badiani A., Robinson T.E. Modulatory effect of environmental stimuli on the susceptibility to amphetamine sensitization: a dose-effect study in rats. J Pharmacol Exp Ther 1998, 287:1007-1014.
10. Levis D.J., Brewer K.E. The neurotic paradox: attempts by two-factor fear theory and alternative avoidance models to resolve the issues associated with sustained avoidance responding in extinction. Handbook of contemporary learning theories 2001, 561-597. Lawrence Erlbaum Associates, Mahwah, NJ. R.R. Mowrer, S.B. Klein (Eds.).
11. Wadenberg M.L., Hicks P.B. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics. Neurosci Biobehav Rev 1999, 23:851-862.
12. Moutoussis M., Williams J., Dayan P., Bentall R.P. Persecutory delusions and the conditioned avoidance paradigm: towards an integration of the psychology and biology of paranoia. Cogn Neuropsychiatry 2007, 12:495-510.
13. Wadenberg M.L., Soliman A., VanderSpek S.C., Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 2001, 25:633-641.
14. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol (Copenh) 1982, 51:321-329.
15. Bignami G. Effects of neuroleptics, ethanol, hypnotic-sedatives, tranquilizers, narcotics, and minor stimulants in aversive paradigms. Psychopharmacology of aversively motivated behavior 1978, 385-453. Plenum Press, New York and London. H. Anisman, G. Bignami (Eds.).
16. van der Heyden J.A., Bradford L.D. A rapidly acquired one-way conditioned avoidance procedure in rats as a primary screening test for antipsychotics: influence of shock intensity on avoidance performance. Behav Brain Res 1988, 31:61-67.
17. Shannon H.E., Hart J.C., Bymaster F.P., Calligaro D.O., DeLapp N.W., Mitch C.H., et al. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. J Pharmacol Exp Ther 1999, 290:901-907.
18. Feng M., Sui N., Li M. Environmental and behavioral controls of the expression of clozapine tolerance: evidence from a novel across-model transfer paradigm. Behav Brain Res 2013, 238:178-187.
19. Li M., Sun T., Mead A. Clozapine, but not olanzapine, disrupts conditioned avoidance response in rats by antagonizing 5-HT2A/2C receptors. J Neural Transm 2012, 119:497-505.
20. Qiao J., Li H., Li M. Olanzapine sensitization and clozapine tolerance: from adolescence to adulthood in the conditioned avoidance response model. Neuropsychopharmacology 2013, 38:513-524.
21. Zhang C., Li M. Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine. Behav Pharmacol 2012, 23:66-79.
22. Mead A., Li M. Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: an interoceptive drug state mechanism. J Psychopharmacol 2010, 24:1045-1053.
23. Li M., Sun T., Zhang C., Hu G. Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning. Psychopharmacology (Berl) 2010, 212:45-57.
24. Antelman S.M., Chiodo L.A. Repeated antidepressant treatments induce a long-lasting dopamine autoreceptor subsensitivity: is daily treatment necessary for clinical efficacy [proceedings]. Psychopharmacol Bull 1981, 17:92-94.
25. Shahid M., Walker G.B., Zorn S.H., Wong E.H. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009, 23:65-73.
26. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005, 10:79-104.
27. Moreno M., Lopez-Moreno J.A., Rodriguez de Fonseca F., Navarro M. Behavioural effects of quinpirole following withdrawal of chronic treatment with the CB1 agonist, HU-210, in rats. Behav Pharmacol 2005, 16:441-446.
28. Luque-Rojas M.J., Galeano P., Suarez J., Araos P., Santin L.J., de Fonseca F.R., et al. Hyperactivity induced by the dopamine D2/D3 receptor agonist quinpirole is attenuated by inhibitors of endocannabinoid degradation in mice. Int J Neuropsychopharmacol 2013, 16:661-676.
29. Szumlinski K.K., Goodwill A.M., Szechtman H. Locomotor sensitization to quinpirole in rats: effects of drug abstinence and sex. Psychopharmacology 2000, 152:304-311.
30. Szumlinski K.K., Allan M., Talangbayan H., Tracey A., Szechtman H. Locomotor sensitization to quinpirole: environment-modulated increase in efficacy and context-dependent increase in potency. Psychopharmacology 1997, 134:193-200.
31. Tenk C.M., Foley K.A., Kavaliers M., Ossenkopp K.P. Neonatal immune system activation with lipopolysaccharide enhances behavioural sensitization to the dopamine agonist, quinpirole, in adult female but not male rats. Brain Behav Immun 2007, 21:935-945.
32. Vorhees C.V., Johnson H.L., Burns L.N., Williams M.T. Developmental treatment with the dopamine D2/3 agonist quinpirole selectively impairs spatial learning in the Morris water maze. Neurotoxicol Teratol 2009, 31:1-10.
33. Franberg O., Wiker C., Marcus M.M., Konradsson A., Jardemark K., Schilstrom B., et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) 2008, 196:417-429.
34. Marston H.M., Young J.W., Martin F.D., Serpa K.A., Moore C.L., Wong E.H., et al. Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology (Berl) 2009, 206:699-714.
35. Li M., Fletcher P.J., Kapur S. Time course of the antipsychotic effect and the underlying behavioral mechanisms. Neuropsychopharmacology 2007, 32:263-272.
36. Li M., He W., Mead A. Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus. Behav Pharmacol 2009, 20:84-98.
37. Zhang C., Fang Y., Li M. Olanzapine and risperidone disrupt conditioned avoidance responding by selectively weakening motivational salience of conditioned stimulus: further evidence. Pharmacol Biochem Behav 2011, 98:155-160.
38. Aguilar M.A., Rodriguez-Arias M., Mari-Sanmillan M.I., Minarro J. Effects of risperidone on conditioned avoidance responding in male mice. Behav Pharmacol 1997, 8:669-676.
39. Nakamura S., Yue J.L., Goshima Y., Miyamae T., Ueda H., Misu Y. Non-effective dose of exogenously applied l-dopa itself stereoselectively potentiates postsynaptic D2 receptor-mediated locomotor activities of conscious rats. Neurosci Lett 1994, 170:22-26.
40. Prosser E.S., Pruthi R., Csernansky J.G. Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride. Psychopharmacology (Berl) 1989, 99:109-116.
41. Koller W., Herbster G., Anderson D., Wack R., Gordon J. Quinpirole hydrochloride, a potential anti-parkinsonism drug. Neuropharmacology 1987, 26:1031-1036.
42. Feng M., Sui N., Li M. Avoidance disruptive effect of clozapine and olanzapine is potentiated by increasing the test trials: further test of the motivational salience hypothesis. Pharmacol Biochem Behav 2013, 103:467-473.
43. Klein A., Schmidt W.J. Catalepsy intensifies context-dependently irrespective of whether it is induced by intermittent or chronic dopamine deficiency. Behav Pharmacol 2003, 14:49-53.
44. Li M., He E., Volf N. Time course of the attenuation effect of repeated antipsychotic treatment on prepulse inhibition disruption induced by repeated phencyclidine treatment. Pharmacol Biochem Behav 2011, 98:559-569.
45. Sun T., Hu G., Li M. Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs. Eur J Pharmacol 2009, 602:334-342.
46. Varvel S.A., Vann R.E., Wise L.E., Philibin S.D., Porter J.H. Effects of antipsychotic drugs on operant responding after acute and repeated administration. Psychopharmacology (Berl) 2002, 160:182-191.
47. Qin R., Chen Y., Li M. Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity. Neuropharmacology 2013, 75C:356-364.
48. Maes J.H., Vossen J.M. Conditional control by midazolam and amphetamine in a rapid appetitive discrimination procedure. Eur J Pharmacol 1997, 319:5-11.
49. Lieberman J.A., Bymaster F.P., Meltzer H.Y., Deutch A.Y., Duncan G.E., Marx C.E., et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008, 60:358-403.
50. Meltzer H.Y., Matsubara S., Lee J.C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989, 25:390-392.
51. Allen J.A., Yost J.M., Setola V., Chen X., Sassano M.F., Chen M., et al. Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A 2011, 108:18488-18493.
52. Konradi C., Heckers S. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry 2001, 50:729-742.
53. Tarazi F.I., Zhang K., Baldessarini R.J. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2001, 297:711-717.
54. Tarazi F.I., Moran-Gates T., Wong E.H., Henry B., Shahid M. Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology (Berl) 2008, 198:103-111.
55. Silvestri S., Seeman M.V., Negrete J.C., Houle S., Shammi C.M., Remington G.J., et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 2000, 152:174-180.
56. Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 2006, 10:515-531.
57. Meltzer H.Y., Dritselis A., Yasothan U., Kirkpatrick P. Asenapine. Nat Rev Drug Discov 2009, 8:843-844.
58. Tarazi F.I., Moran-Gates T., Wong E.H., Henry B., Shahid M. Asenapine induces differential regional effects on serotonin receptor subtypes. J Psychopharmacol 2010, 24:341-348.
59. Choi Y.K., Moran-Gates T., Gardner M.P., Tarazi F.I. Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats. Eur Neuropsychopharmacol 2010, 20:187-194.
60. Franberg O., Marcus M.M., Svensson T.H. Involvement of 5-HT(2A) receptor and alpha(2)-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow. Synapse 2012, 66:650-660.
61. Choi Y.K., Wong E.H., Henry B., Shahid M., Tarazi F.I. Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors. Int J Neuropsychopharmacol 2010, 13:405-410.
62. Tarazi F.I., Neill J.C. The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania. Expert Opin Drug Discov 2013, 8(1):93-103.
63. Antelman S.M., Levine J., Gershon S. Time-dependent sensitization: the odyssey of a scientific heresy from the laboratory to the door of the clinic. Mol Psychiatry 2000, 5:350-356.
64. Agid O., Seeman P., Kapur S. The "delayed onset" of antipsychotic action - an idea whose time has come and gone. J Psychiatry Neurosci 2006, 31:93-100.
65. Kapur S. A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Mol Psychiatry 1998, 3:135-140.
66. Remington G., Seeman P., Shammi C., Mann S., Kapur S. "Extended" antipsychotic dosing: rationale and pilot data. J Clin Psychopharmacol 2005, 25:611-613.
67. Remington G., Seeman P., Feingold A., Mann S., Shammi C., Kapur S. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2011, 72:1042-1048.